CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing… Read more
CARsgen Therapeutics Holdings Limited (CRTHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of April 2019: -0.015x
Based on the latest financial reports, CARsgen Therapeutics Holdings Limited (CRTHF) has a cash flow conversion efficiency ratio of -0.015x as of April 2019.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($860.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CARsgen Therapeutics Holdings Limited - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how CARsgen Therapeutics Holdings Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CARsgen Therapeutics Holdings Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CARsgen Therapeutics Holdings Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SEMLER SCIENTIFIC DL-001
F:6FA
|
N/A |
|
ShaMaran Petroleum Corp
PINK:SHASF
|
0.026x |
|
Longxing Chemical Stock Co Ltd
SHE:002442
|
-0.009x |
|
Satellogic V Inc
NASDAQ:SATL
|
0.147x |
|
AXISCADES Technologies Limited
NSE:AXISCADES
|
0.019x |
|
Jayaswal Neco Industries Limited
NSE:JAYNECOIND
|
0.260x |
|
Solaris Resources Inc.
OTCQB:SLSR
|
0.296x |
|
Era Co Ltd
SHE:002641
|
0.002x |
Annual Cash Flow Conversion Efficiency for CARsgen Therapeutics Holdings Limited (2014–2024)
The table below shows the annual cash flow conversion efficiency of CARsgen Therapeutics Holdings Limited from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-10-31 | $1.06 Billion | $-409.69 Million | -0.388x | -53.54% |
| 2023-10-31 | $1.80 Billion | $-454.94 Million | -0.253x | +2.89% |
| 2022-10-31 | $2.47 Billion | $-643.05 Million | -0.260x | -52.08% |
| 2021-10-31 | $3.00 Billion | $-512.32 Million | -0.171x | -197.09% |
| 2020-10-31 | $-1.68 Billion | $-295.15 Million | 0.176x | +148.34% |
| 2018-10-31 | $878.60 Million | $62.30 Million | 0.071x | +148.88% |
| 2017-10-31 | $817.80 Million | $23.30 Million | 0.028x | -86.68% |
| 2016-10-31 | $719.20 Million | $153.80 Million | 0.214x | +473.93% |
| 2015-10-31 | $630.70 Million | $23.50 Million | 0.037x | +151.52% |
| 2014-10-31 | $536.50 Million | $-38.80 Million | -0.072x | -- |